An article published in the peer-reviewed Medicolegal and Bioethics presents a rare challenge not just to the ethics but also to the science of using non human primates in research.
More Press Releases
Dec 6, ’11
Jun 23, ’11
In a letter addressed to EU Commissioner John Dalli, Antidote Europe points to the growing number of scientists who consider animal tests to be about as predictive as, or less than, tossing a coin.
Jan 6, ’11
Antidote Europe welcomes recent French media reports warning the public about dangerous medicines.
Oct 12, ’10
The campaign’s report presents an immediate science strategy to end poisoning tests on non-human primates.
Jul 6, ’10
Antidote Europe has criticised the French government for taking very timid measures to ban the synthetic chemical bisphenol A (BPA). It makes no sense to protect nursing infants by banning the substance in baby bottles when their mothers are exposed to it on a daily basis — not to mention the effect on the foetuses of pregnant women.
Feb 10, ’10
Antidote Europe has re-issued its warning on bisphenol A, criticizing the French Food Safety Agency (AFSSA) on its confused and unclear public announcements regarding this chemical.
Nov 26, ’09
Antidote Europe was awarded the Pietro Croce prize.
Aug 5, ’09
Antidote Europe has launched a public campaign regarding the dangers of bisphenol A and has duly informed the new president of the European Parliament.
Jul 8, ’09
It is difficult to understand why food safety agencies continue to place their trust in ambiguous animal data when human data is readily available. The fact that DES and BPA share striking similarities in their structures is extremely worrisome and lends weight to the possibility that BPA is a “chemical time bomb” in terms of our health.
Will the United States be the first country to stop testing chemicals on animals?
Thu 30 Aug 2007
A recent report published by the US National Research Council (NRC), entitled “Toxicity testing in the Twenty-first century: a vision and a strategy”, acknowledges the importance of using biological material of human origin, in conjunction with the modern science of toxicogenomics. Antidote Europe sees this as a positive development and as confirmation of its own novel approach to the science of toxicity testing, which, together with the efforts of other European groups, has ensured that these methods will be incorporated in the new EU chemicals testing program, REACH, which entered into force on 1st June, 2007.
The US National Research Council (NRC) recently published a report entitled “Toxicity testing in the Twenty-first century: a vision and a strategy”, in which it criticises the shortcomings of animal experiments and promotes the idea of utilising cells and tissues of human origin. That the shift away from laboratory animals makes good business sense is confirmed by the fact that the chemical and pharmaceutical industry have begun to adopt this new approach. It could not have come at a better time for the EU, whose chemical testing program, REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) has just entered into force.
Based on the European Commission’s own admission that we live in a sea of 100,000 chemicals, in addition to the substantial weight of scientific evidence linking long-term exposure to chemical “cocktails” it is worrying, but not surprising, that we are in the grip of a major increase in serious health problems. These include many forms of juvenile and adult cancer, neurodegenerative conditions (such as Alzheimer’s and Parkinson’s disease) and asthma, to name the most common. The reason why so many harmful chemicals have managed to slip through the “safety screen” of our regulatory authorities has been summed up succinctly by Professor Thomas Hartung, director of ECVAM (European Centre for the Validation of Alternative Methods) and a scientific advisor to the European Commission, who described animal tests as representing “simply bad science”.
A truly scientific approach to toxicity testing is therefore well overdue. The NRC report fully recognises the pitfalls inherent in trying to apply animal data to humans. In its place it strongly recommends the use of modern methods of chemical testing, based chiefly on gene studies in cell culture and computational biology. This new approach, according to the NRC, has the potential to transform “toxicity testing from a system based on whole animal testing to one founded primarily on in vitro methods that evaluate changes in biologic processes using cells, cell lines, or cellular components, preferably of human origin.”
Interestingly, the pharmaceutical and the chemical industry do not necessarily share the same strategy in this respect. An article published in an early August edition of the journal Chemical Engineering News makes clear this point in a reference to the NRC report. Whereas the pharmaceutical industry relies increasingly on tissues of human origin in order to screen promising drugs, the chemical industry traditionally looks to animal tests to help market its products. In fact, it makes good economic sense for EU industrialists to embrace human-based tests for REACH, since animal testing turns out to be far more expensive, in addition to being “simply bad science”.
Antidote Europe and similar-minded groups have succeeded in pushing for some of the NRC recommendations to be incorporated in the REACH legislation. In addition, Antidote Europe’s scientists have contributed their expertise in providing a novel approach to these human-based testing methods, whereby hundreds of chemical substances can be tested over a very short period of time, as an early screen. Results are obtained in less than a week, whereas this type of test in animals can take up to two years to complete. Similarly, the new approach is considerably more cost-effective, in the range of 10,000 euros per substance versus several hundred thousand euros using whole animals.